Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Webcast to be Held on Friday, October 20, 2023 at 8:00 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.

The event will feature presentations and discussions with:

• Jamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Institute for Hispanic Health, Professor of Pediatrics, Texas A&M University and Director, Infectious Diseases, Driscoll Children’s Hospital
• Tom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS – Professor of Respiratory Medicine and Associate Dean, University of Southampton and Faculty of Medicine, Southampton General Hospital

The event will be led by Jay R. Luly, PhD, President and Chief Executive Officer of Enanta, who will be joined by Scott T. Rottinghaus, MD, Senior Vice President and Chief Medical Officer, and John DeVincenzo, MD, Vice President of Translational Virology.

Complete speaker biographies can be found on the Event registration page here.

Event details are as follows:

Respiratory Syncytial Virus: The Evolving Treatment Landscape
Date and Time: October 20, 2023 at 8:00 a.m. ET
Webcast Link: Register

A webcast of the event will be available on the investor relations page of the Enanta Pharmaceuticals website at https://ir.enanta.com/events-presentations. A replay of the webcast will be archived on Enanta’s website for at least 30 days following the presentation.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.